Sun Pharmaceutical Industries Ltd.
Overview
-
Headquartered in Mumbai, India; established in 1983 by Dilip Shanghvi.
-
India’s largest pharmaceutical company and a global leader in specialty generics.
-
Operates in over 100 countries across therapeutic areas like dermatology, oncology, and cardiology.
Role & Responsibilities
-
Develops, manufactures, and markets formulations and APIs.
-
Ensures compliance, quality, and innovation across its R&D and manufacturing facilities.
-
Focuses on specialty drugs, global expansion, and healthcare access.
Annual Revenue (Recent)
-
FY2025 revenue: approximately ₹525.78 billion with 8.4% growth.
-
Specialty segment contributed over 18% of total sales.
-
R&D investment stood at around 6.7% of total revenue.
Recent Updates
-
Reported strong quarterly profit with robust demand in rare-disease portfolio.
-
Expanding specialty medicine business in dermatology and ophthalmology.
-
Strengthening global footprint through new product launches and partnerships.
Sandoz Group AG
Overview
-
Headquartered in Basel, Switzerland; originally founded in 1886, spun off from Novartis in 2023.
-
A global leader in generics and biosimilars, operating in over 100 countries.
-
Focuses on making high-quality medicines accessible worldwide.
Role & Responsibilities
-
Develops and distributes generic medicines, biosimilars, and APIs.
-
Drives sustainable access through efficient production and regulatory excellence.
-
Prioritizes affordability, innovation, and environmental responsibility.
Annual Revenue (Recent)
-
FY2024 revenue exceeded USD 10 billion.
-
Core EBITDA reached USD 2.1 billion with a 20% margin.
-
Over 900 million patient treatments delivered annually.
Recent Updates
-
Completed separation from Novartis, becoming a standalone company.
-
Expanding biosimilar pipeline and global market share.
-
Strengthened portfolio through strategic R&D and digital initiatives.
Teva Pharmaceutical Industries Ltd.
Overview
-
Headquartered in Petah Tikva, Israel; founded in 1901.
-
Among the world’s largest generic drug manufacturers.
-
Operates across over 60 countries with both generic and branded portfolios.
Role & Responsibilities
-
Manufactures and markets generics, specialty drugs, and APIs.
-
Focuses on neuroscience, respiratory, oncology, and chronic disease therapies.
-
Committed to innovation, efficiency, and sustainable healthcare solutions.
Annual Revenue (Recent)
-
FY2024 revenue: around USD 16.5 billion, up 4.4% year-over-year.
-
Continued strong growth in generics and key brands like Austedo® and Ajovy®.
-
Improved margins through cost optimization and restructuring.
Recent Updates
-
Achieved second consecutive year of growth in 2024.
-
Strengthened global leadership in complex generics.
-
Enhanced operational efficiency and reduced long-term debt.
Cipla Ltd.
Overview
-
Headquartered in Mumbai, India; founded in 1935.
-
Global pharmaceutical firm with presence in 80+ countries.
-
Known for respiratory, antiviral, and chronic therapy innovations.
Role & Responsibilities
-
Manufactures and markets a wide range of generics and APIs.
-
Invests in innovation, inhalation technology, and complex generics.
-
Focuses on patient accessibility, sustainability, and digital transformation.
Annual Revenue (Recent)
-
FY2025 revenue: approximately ₹27,547 crore with ~7% growth.
-
PAT growth of 28% and EBITDA margin around 25.9%.
-
Strong domestic and export performance driving profitability.
Recent Updates
-
Posted record quarterly profit in FY25.
-
Announced long-term growth targets and sustainability goals.
-
Expanding AI-driven drug development and digital healthcare initiatives.
